Spero Therapeutics Inc
NASDAQ:SPRO
Intrinsic Value
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infec... [ Read More ]
The intrinsic value of one SPRO stock under the Base Case scenario is 17.03 USD. Compared to the current market price of 1.72 USD, Spero Therapeutics Inc is Undervalued by 90%.
Valuation Backtest
Spero Therapeutics Inc
Run backtest to discover the historical profit from buying and selling SPRO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Spero Therapeutics Inc's business.
What risks and challenges
does Spero Therapeutics Inc face in the near future?
Summarize the latest earnings report
of Spero Therapeutics Inc.
Provide P/E
for Spero Therapeutics Inc and its competitors.
Balance Sheet Decomposition
Spero Therapeutics Inc
Current Assets | 131.2m |
Cash & Short-Term Investments | 76.3m |
Receivables | 50.7m |
Other Current Assets | 4.2m |
Non-Current Assets | 51.2m |
PP&E | 4.2m |
Other Non-Current Assets | 47m |
Current Liabilities | 37.2m |
Accounts Payable | 1.4m |
Accrued Liabilities | 8.3m |
Other Current Liabilities | 27.5m |
Non-Current Liabilities | 38.3m |
Other Non-Current Liabilities | 38.3m |
Earnings Waterfall
Spero Therapeutics Inc
Revenue
|
103.8m
USD
|
Operating Expenses
|
-77m
USD
|
Operating Income
|
26.8m
USD
|
Other Expenses
|
-4m
USD
|
Net Income
|
22.8m
USD
|
Free Cash Flow Analysis
Spero Therapeutics Inc
What is Free Cash Flow?
SPRO Profitability Score
Profitability Due Diligence
Spero Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Spero Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
SPRO Solvency Score
Solvency Due Diligence
Spero Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Spero Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SPRO Price Targets Summary
Spero Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for SPRO is 7.65 USD with a low forecast of 7.07 USD and a high forecast of 8.4 USD.
Ownership
SPRO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SPRO Price
Spero Therapeutics Inc
Average Annual Return | -11.33% |
Standard Deviation of Annual Returns | 70.13% |
Max Drawdown | -97% |
Market Capitalization | 91.2m USD |
Shares Outstanding | 52 999 300 |
Percentage of Shares Shorted | 1.3% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
Contact
IPO
Employees
Officers
The intrinsic value of one SPRO stock under the Base Case scenario is 17.03 USD.
Compared to the current market price of 1.72 USD, Spero Therapeutics Inc is Undervalued by 90%.